High Plasma Levels of Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 Are Associated With Inflammation and Cardiometabolic Risk Profiles in Pediatric Overweight and Obesity.

التفاصيل البيبلوغرافية
العنوان:	High Plasma Levels of Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 Are Associated With Inflammation and Cardiometabolic Risk Profiles in Pediatric Overweight and Obesity.
المؤلفون:	Stinson SE; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Jonsson AE; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Andersen MK; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Lund MAV; The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics Holbæk Hospital Holbæk Denmark.; Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Denmark., Holm LA; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark.; The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics Holbæk Hospital Holbæk Denmark., Fonvig CE; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark.; The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics Holbæk Hospital Holbæk Denmark.; Department of Pediatrics Kolding Hospital a part of Lillebælt Hospital Kolding Denmark., Huang Y; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Stankevič E; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Juel HB; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Ängquist L; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Sørensen TIA; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark.; Department of Public Health, Faculty of Health and Medical Sciences University of Copenhagen Denmark., Ongstad EL; Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD., Gaddipati R; Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD., Grimsby J; Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD.; Regeneron Pharmaceuticals, Inc. Tarrytown NY., Rhodes CJ; Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gaithersburg MD., Pedersen O; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark., Christiansen M; The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics Holbæk Hospital Holbæk Denmark.; Department for Congenital Disorders Statens Serum Institute Copenhagen Denmark., Holm JC; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark.; The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics Holbæk Hospital Holbæk Denmark.; Faculty of Health and Medical Sciences University of Copenhagen Denmark., Hansen T; Novo Nordisk Foundation Center for Basic Metabolic Research Faculty of Health and Medical Sciences, University of Copenhagen Denmark.
المصدر:	Journal of the American Heart Association [J Am Heart Assoc] 2023 Feb 07; Vol. 12 (3), pp. e8145. Date of Electronic Publication: 2023 Jan 25.
نوع المنشور:	Journal Article; Research Support, Non-U.S. Gov't
اللغة:	English
بيانات الدورية:	Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Oxford : Wiley-Blackwell
مواضيع طبية MeSH:	Cardiovascular Diseases* , Diabetes Mellitus, Type 2* , Pediatric Obesity/diagnosis , Pediatric Obesity/epidemiology , Scavenger Receptors, Class E*/blood, Adolescent ; Child ; Humans ; Alanine Transaminase ; Biomarkers ; Cholesterol ; Cross-Sectional Studies ; Inflammation/epidemiology ; Lipoproteins, LDL ; Overweight/epidemiology
مستخلص:	Background Lectin-like oxidized low-density lipoprotein (ox-LDL) receptor-1 is a scavenger receptor for oxidized low-density lipoprotein. In adults, higher soluble lectin-like ox-LDL receptor-1 (sLOX-1) levels are associated with cardiovascular disease, type 2 diabetes, and obesity, but a similar link in pediatric overweight/obesity remains uncertain. Methods and Results Analyses were based on the cross-sectional HOLBAEK Study, including 4- to 19-year-olds from an obesity clinic group with body mass index >90th percentile (n=1815) and from a population-based group (n=2039). Fasting plasma levels of sLOX-1 and inflammatory markers were quantified, cardiometabolic risk profiles were assessed, and linear and logistic regression analyses were performed. Pubertal/postpubertal children and adolescents from the obesity clinic group exhibited higher sLOX-1 levels compared with the population ( P <0.001). sLOX-1 positively associated with proinflammatory cytokines, matrix metalloproteinases, body mass index SD score, waist SD score, body fat %, plasma alanine aminotransferase, serum high-sensitivity C-reactive protein, plasma low-density lipoprotein cholesterol, triglycerides, systolic and diastolic blood pressure SD score, and inversely associated with plasma high-density lipoprotein cholesterol (all P <0.05). sLOX-1 positively associated with high alanine aminotransferase (odds ratio [OR], 1.16, P =4.1 E-04), insulin resistance (OR, 1.16, P =8.6 E-04), dyslipidemia (OR, 1.25, P =1.8 E-07), and hypertension (OR, 1.12, P =0.02). Conclusions sLOX-1 levels were elevated during and after puberty in children and adolescents with overweight/obesity compared with population-based peers and associated with inflammatory markers and worsened cardiometabolic risk profiles. sLOX-1 may serve as an early marker of cardiometabolic risk and inflammation in pediatric overweight/obesity. Registration The HOLBAEK Study, formerly known as The Danish Childhood Obesity Biobank, ClinicalTrials.gov identifier number NCT00928473, https://clinicaltrials.gov/ct2/show/NCT00928473 (registered June 2009).
References:	J Am Heart Assoc. 2020 Jan 7;9(1):e013803. (PMID: 31902328) Circulation. 2003 Feb 4;107(4):612-7. (PMID: 12566375) J Cardiovasc Transl Res. 2020 Apr;13(2):204-214. (PMID: 31428922) Antioxidants (Basel). 2019 Jul 11;8(7):. (PMID: 31336709) Pediatr Diabetes. 2019 Aug;20(5):538-548. (PMID: 31074070) Int J Obes (Lond). 2011 Jun;35(6):793-9. (PMID: 20856256) Arch Dis Child. 1970 Feb;45(239):13-23. (PMID: 5440182) Circulation. 2008 Mar 4;117(9):1216-27. (PMID: 18316498) N Engl J Med. 2007 Dec 6;357(23):2329-37. (PMID: 18057335) Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):816-21. (PMID: 12637341) Biochim Biophys Acta. 2010 Mar;1801(3):338-49. (PMID: 20056169) Pediatrics. 2015 Jan;135(1):86-93. (PMID: 25535262) Clin Chim Acta. 2015 Oct 23;450:11-4. (PMID: 26169157) Metabolism. 2009 Sep;58(9):1209-14. (PMID: 19592055) Int J Pediatr Obes. 2011 Aug;6(3-4):188-96. (PMID: 21529264) J Am Heart Assoc. 2018 Jan 12;7(2):. (PMID: 29330254) J Lipid Res. 2008 Jul;49(7):1438-44. (PMID: 18408244) Eur Heart J. 2022 May 14;43(19):1849-1860. (PMID: 35567560) Circ J. 2011;75(12):2862-71. (PMID: 21937834) Mol Cell Proteomics. 2011 Apr;10(4):M110.004978. (PMID: 21242282) Obesity (Silver Spring). 2011 Jul;19(7):1415-9. (PMID: 21331062) Mol Biol Rep. 2015 Jun;42(6):1039-47. (PMID: 25416967) PLoS One. 2018 Feb 14;13(2):e0190576. (PMID: 29444114) Atherosclerosis. 2009 Jan;202(1):176-82. (PMID: 18514661) Arch Dis Child. 1969 Jun;44(235):291-303. (PMID: 5785179) Obesity (Silver Spring). 2008 Jun;16(6):1454-6. (PMID: 18388896) J Clin Endocrinol Metab. 2020 Feb 1;105(2):. (PMID: 31617910) Pediatrics. 2011 Dec;128 Suppl 5:S213-56. (PMID: 22084329) Pediatrics. 2017 Sep;140(3):. (PMID: 28827377) Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. (PMID: 33298413) Int J Obes Relat Metab Disord. 2001 Feb;25(2):177-84. (PMID: 11410817) BMC Pediatr. 2017 Apr 28;17(1):116. (PMID: 28454530) Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):153-166. (PMID: 33176449) N Engl J Med. 1998 Jun 4;338(23):1650-6. (PMID: 9614255) Nat Metab. 2020 Oct;2(10):1135-1148. (PMID: 33067605) Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):95-106. (PMID: 9012643) Clin Chim Acta. 2019 Apr;491:24-29. (PMID: 30639239) Biochemistry. 2016 Aug 16;55(32):4437-44. (PMID: 27419271) Int J Obes (Lond). 2014 Sep;38 Suppl 2:S26-31. (PMID: 25376218) Pediatr Diabetes. 2010 Dec;11(8):552-5. (PMID: 20102528) Mediators Inflamm. 2013;2013:152786. (PMID: 23935243) J Am Heart Assoc. 2019 Feb 19;8(4):e009874. (PMID: 30744454) J Am Coll Cardiol. 2017 Jun 6;69(22):2759-2768. (PMID: 28571642) PLoS One. 2020 Mar 17;15(3):e0229184. (PMID: 32182251) J Biol Chem. 2008 Apr 18;283(16):10226-31. (PMID: 18182394) Am J Clin Nutr. 2000 Nov;72(5 Suppl):1307S-1315S. (PMID: 11063473) Pediatr Res. 2015 Dec;78(6):723-9. (PMID: 26331767) Circulation. 2000 Jun 27;101(25):2889-95. (PMID: 10869259) Nutr Metab Cardiovasc Dis. 2020 Aug 28;30(9):1544-1553. (PMID: 32571613) Lipids. 2008 Oct;43(10):945-50. (PMID: 18781352) Lancet Diabetes Endocrinol. 2020 Jul;8(7):616-627. (PMID: 32559477) Circ Res. 2020 May 22;126(11):1613-1627. (PMID: 32437301)
فهرسة مساهمة:	Keywords: adolescent; child; obesity; overweight; soluble lectin‐like oxidized low‐density lipoprotein receptor‐1
سلسلة جزيئية:	ClinicalTrials.gov NCT00928473
المشرفين على المادة:	EC 2.6.1.2 (Alanine Transaminase) 0 (Biomarkers) 97C5T2UQ7J (Cholesterol) 0 (Lipoproteins, LDL) 0 (Scavenger Receptors, Class E)
تواريخ الأحداث:	Date Created: 20230125 Date Completed: 20230302 Latest Revision: 20230302
رمز التحديث:	20230303
مُعرف محوري في PubMed:	PMC9973661
DOI:	10.1161/JAHA.122.027042
PMID:	36695299
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	2047-9980
DOI:	10.1161/JAHA.122.027042